GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Shares Outstanding (EOP)

Everest Medicines (HKSE:01952) Shares Outstanding (EOP) : 322.3 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Everest Medicines's shares outstanding for the quarter that ended in Jun. 2024 was 322.3 Mil.

Everest Medicines's quarterly shares outstanding increased from Dec. 2023 (319.4 Mil) to Jun. 2024 (322.3 Mil). It means Everest Medicines issued new shares from Dec. 2023 to Jun. 2024 .

Everest Medicines's annual shares outstanding increased from Dec. 2022 (305.5 Mil) to Dec. 2023 (319.4 Mil). It means Everest Medicines issued new shares from Dec. 2022 to Dec. 2023 .


Everest Medicines Shares Outstanding (EOP) Historical Data

The historical data trend for Everest Medicines's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Shares Outstanding (EOP) Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 283.69 293.22 294.41 305.46 319.36

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 296.97 305.46 312.87 319.36 322.29

Competitive Comparison of Everest Medicines's Shares Outstanding (EOP)

For the Biotechnology subindustry, Everest Medicines's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Shares Outstanding (EOP) falls into.



Everest Medicines Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Everest Medicines  (HKSE:01952) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Everest Medicines Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Medicines Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Ra Capital Management, L.p. 2102 Investment manager
Kolchinsky Peter 2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Fu Wei 2307 Founder of a discretionary trust who can infl
Janchor Partners Limited 2102 Investment manager
C-bridge Capital Gp, Ltd. 2501 Other
Vistra Trust (singapore) Pte. Limited 2501 Other
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited 2101 Beneficial owner

Everest Medicines Headlines

No Headlines